To explore the effect of SH2D2A deficiency in a more physiological context we used a well-characterized TCR-transgenic model for CD4+ T cell mediated resistance to the MOPC315 mouse myeloma [17], [19], [27]. The gene discussed is SH2D2A; the disease is plasma cell myeloma.